Umberto Capitanio Selected Research

Umberto Capitanio Research Topics

Disease

96	Neoplasms (Cancer) 03/2022 - 04/2008
75	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 11/2008
54	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 07/2008
19	Carcinoma (Carcinomatosis) 02/2022 - 01/2009
18	Kidney Neoplasms (Kidney Cancer) 02/2022 - 12/2011
18	Urinary Bladder Neoplasms (Bladder Cancer) 10/2021 - 05/2009
16	Margins of Excision 03/2022 - 10/2008
16	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2009
9	Chronic Renal Insufficiency 08/2022 - 10/2016
9	Lymphatic Metastasis 09/2021 - 10/2008
6	Disease Progression 01/2022 - 01/2009
6	Acute Kidney Injury (Acute Renal Failure) 07/2021 - 01/2019
5	Thrombosis (Thrombus) 12/2021 - 01/2018
5	Ischemia 11/2021 - 01/2019
5	Erectile Dysfunction 03/2017 - 09/2008
4	Hypertension (High Blood Pressure) 02/2022 - 10/2016
4	Intraoperative Complications 01/2021 - 10/2018
4	Lower Urinary Tract Symptoms 01/2019 - 09/2008
3	Necrosis 01/2022 - 04/2010
3	Frailty 01/2022 - 03/2020
3	Chronic Kidney Failure (Chronic Renal Failure) 11/2021 - 10/2016
3	Carcinoma in Situ 05/2012 - 01/2010
3	Residual Neoplasm 02/2011 - 07/2008
2	Overweight 01/2020 - 03/2012
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019 - 02/2011
2	Hyperplasia 01/2019 - 04/2014
2	Hypogonadism (Hypergonadotropic Hypogonadism) 04/2013 - 09/2011
2	Extranodal Extension 09/2011 - 04/2011
2	Lymphocele 09/2011 - 04/2011
2	Rectal Neoplasms (Rectal Cancer) 10/2010 - 02/2010
2	Renal Insufficiency (Renal Failure) 02/2010 - 06/2009
1	COVID-19 01/2022
1	Oxyphilic Adenoma (Oncocytoma) 04/2021
1	Cicatrix (Scar) 01/2021

Drug/Important Bio-Agent (IBA)

15	pembrolizumabIBA 01/2022 - 01/2020
13	Prostate-Specific Antigen (Semenogelase)IBA 09/2014 - 07/2008
7	AndrogensIBA 12/2018 - 08/2009
7	Testosterone (Sustanon)FDA Link 04/2013 - 04/2011
6	Sex Hormone-Binding GlobulinIBA 04/2013 - 04/2009
5	Indicators and Reagents (Reagents)IBA 01/2022 - 04/2010
4	CreatinineIBA 01/2021 - 07/2013
4	Estradiol (Delestrogen)FDA LinkGeneric 04/2013 - 11/2011
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
3	Hemoglobins (Hemoglobin)IBA 12/2017 - 06/2013
3	SteroidsIBA 04/2013 - 04/2011
2	RNA (Ribonucleic Acid)IBA 02/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 08/2016
2	Complement System Proteins (Complement)IBA 10/2021 - 10/2010
2	Axitinib (AG 013736)IBA 10/2021 - 01/2021
2	NivolumabIBA 10/2021 - 01/2021
2	IpilimumabIBA 10/2021 - 01/2021
2	cabozantinibIBA 10/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2009
2	Biological ProductsIBA 01/2021 - 02/2011
2	VaccinesIBA 01/2018 - 06/2015
2	Gonadal Steroid Hormones (Sex Hormones)IBA 08/2012 - 08/2011
2	Dihydrotachysterol (AT 10)IBA 12/2009 - 02/2009
2	isopropyl cyanoacrylateIBA 03/2009 - 08/2008
1	drospirenone and ethinyl estradiol combination (Yasmin)FDA LinkGeneric 10/2022
1	G250 monoclonal antibodyIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	ChemokinesIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Interleukin-1 (Interleukin 1)IBA 01/2022
1	Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric 01/2022
1	acceleratory factor from growth hormone (AcG)IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Death Domain ReceptorsIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 12/2021
1	lenvatinibIBA 10/2021
1	cyclo(Arg-Pro) (CI 4)IBA 07/2021
1	fluoroazomycin arabinosideIBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021

Therapy/Procedure

97	Nephrectomy 08/2022 - 11/2008
42	Prostatectomy (Retropubic Prostatectomy) 07/2020 - 07/2008
38	Therapeutics 01/2022 - 08/2008
34	Lymph Node Excision (Lymph Node Dissection) 01/2019 - 04/2008
22	Cystectomy 10/2021 - 01/2009
9	Radiotherapy 01/2021 - 02/2009
8	Thrombectomy 12/2021 - 11/2016
7	Nephroureterectomy 01/2022 - 03/2010
6	Warm Ischemia 03/2022 - 10/2018
6	Drug Therapy (Chemotherapy) 01/2022 - 04/2008
5	Length of Stay 01/2022 - 01/2018
5	Immunotherapy 01/2022 - 01/2020
4	Operative Time 01/2021 - 10/2018
4	Metastasectomy 12/2019 - 06/2013
3	Blood Transfusion (Blood Transfusions) 01/2022 - 12/2020
3	Neoadjuvant Therapy 01/2022 - 01/2021
3	Minimally Invasive Surgical Procedures 01/2021 - 08/2019
3	Aftercare (After-Treatment) 01/2021 - 02/2016
3	Adjuvant Chemotherapy 06/2010 - 01/2010
2	Operative Surgical Procedures 08/2020 - 05/2016
2	Adjuvant Radiotherapy 06/2013 - 03/2009
2	Transurethral Resection of Prostate (TURP) 05/2011 - 08/2009
1	Robotic Surgical Procedures 12/2021
1	Salvage Therapy 12/2021